APHRIA INC - NYSE APHA - 158% Increase In Adult-Use-Sales

Canadian Marijuana Stock  - Up And Away - Watch This CNBC Cramer Interview

Other Top Stocks - Wall Street Daily 

FEATURED HIGHLIGHTS  - CANNABIS SCIENCE

Cannabis Science ( CBIS - OTC ) recently hit $0.065 on high volume topping 41 million shares, and is presently consolidating . We expect this company to again attempt a breakout above its yearly high. This company has the goods , a highly experienced  management team and a rapidly expanding market place. Serious investors should ride the next wave and place these shares on their BUY LIST  

Cannabis Science Canada recently initiated operations , acquiring land and licenses from operators already doing business in Canada. We anticipate an aggressive expansion into Canada propelling the shares still higher. 

Cannabis Science’s primary objective is to research and develop U.S. Food and Drug Administration (FDA)-approved, cannabinoid-based medicine to fight a number of targeted critical ailments, including various Cancers, Neurological Conditions, PTSD, Sleep Deprivation, Chronic Pain, HIV/AIDS, Autism, Parkinson’s Disease, Epilepsy, Chronic Obstructive Pulmonary Disease (COPD), and others. . MORE NEWS ON CBIS

CBIS ETF - MARIJUANA

APHRIA - LATEST RESULTS

Aphria Inc ( NYSE APHA ) shares climbed significantly  after reporting a huge increase in quarterly net revenue. Fourth-quarter net revenue came in at CA$128.6 million. This is up from CA$12.03 million in the same period last year, an increase of 969%.

This is a consumer based company with little downside . Marijuana and its by-products are insulated from any economic downturn.

This is only the beginning and this stock has a long way to go . APHA reached a 12 month high of $16.88 last year and we expect a test of last years high . Serious Investors should place these shares immediately on their BUY LIST

Aphria Inc (NYSE: APHA) shares soared Thursday afternoon after reporting a huge increase in quarterly net revenue.

Fourth-quarter net revenue came in at CA$128.6 million. This is up from CA$12.03 million in the same period last year, an increase of 969%

"It's a new day at Aphria. Our team's solid execution across key areas of our business resulted in strong adult-use revenue growth and a profitable fourth quarter," said Irwin Simon. "Over the last six months, our organization identified immediate priorities to help generate substantial progress near-term and long-term. We built upon existing business fundamentals and capabilities, streamlined processes, strengthened governance, and focused on building brand awareness.

"Together, we have nurtured an entrepreneurial culture of accountability through data-driven decision-making for value creation in the global medical and adult-use cannabis industry."

Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 — click here to learn more!

Highlights

  • Net revenue increased 75% sequentially
  • Revenue for adult-use cannabis of CA$18.5 million, up 158% sequentially
  • Ended quarter with CA$571 million of cash

READ ENTIRE PRESS RELEASE

 

 

Other Top Stocks - Wall Street Daily